Loading...

Becton, Dickinson and Company

BDXBNYSE
Healthcare
Medical - Instruments & Supplies
$48.16
$0.66(1.39%)

Becton, Dickinson and Company (BDXB) Financial Performance & Income Statement Overview

Explore the financials of Becton, Dickinson and Company (BDXB), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
4.16%
4.16%
Operating Income Growth
13.55%
13.55%
Net Income Growth
14.89%
14.89%
Operating Cash Flow Growth
28.60%
28.60%
Operating Margin
11.71%
11.71%
Gross Margin
32.81%
32.81%
Net Profit Margin
7.31%
7.31%
ROE
6.14%
6.14%
ROIC
5.36%
5.36%

Becton, Dickinson and Company (BDXB) Income Statement & Financial Overview

Explore comprehensive income reports for Becton, Dickinson and Company BDXB, broken down by year and quarter.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$5.17B$5.44B$4.99B$5.04B
Cost of Revenue$2.93B$2.95B$2.68B$2.74B
Gross Profit$2.23B$2.49B$2.31B$2.30B
Gross Profit Ratio$0.43$0.46$0.46$0.46
R&D Expenses$343.00M$302.00M$299.00M$299.00M
SG&A Expenses$1.32B$1.26B$1.20B$1.19B
Operating Expenses$1.78B$1.86B$1.59B$1.47B
Total Costs & Expenses$4.71B$4.62B$4.28B$4.21B
Interest Income$23.00M$55.00M$48.00M$26.00M
Interest Expense$155.00M$155.00M$137.00M$125.00M
Depreciation & Amortization$0.00$47.00M$568.00M$571.00M
EBITDA$453.00M$697.00M$1.21B$1.33B
EBITDA Ratio$0.09$0.13$0.26$0.28
Operating Income$453.00M$650.00M$715.00M$835.00M
Operating Income Ratio$0.09$0.12$0.14$0.17
Other Income/Expenses (Net)-$147.00M-$136.00M-$215.00M-$101.00M
Income Before Tax$306.00M$514.00M$500.00M$633.00M
Income Before Tax Ratio$0.06$0.09$0.10$0.13
Income Tax Expense$3.00M$114.00M$13.00M$96.00M
Net Income$303.00M$400.00M$487.00M$537.00M
Net Income Ratio$0.06$0.07$0.10$0.11
EPS$1.05-$4.51$1.68$1.85
Diluted EPS$1.04-$4.49$1.68$1.85
Weighted Avg Shares Outstanding$289.50M$289.61M$289.56M$289.52M
Weighted Avg Shares Outstanding (Diluted)$290.39M$290.60M$290.25M$290.34M

The company's financials show resilient growth, with revenue advancing from $5.04B in Q2 2024 to $5.17B in Q1 2025. Gross profit remained healthy with margins at 43% in Q1 2025 compared to 46% in Q2 2024. Operating income hit $453.00M last quarter, sustaining a consistent 9% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $453.00M. Net income dropped to $303.00M, while earnings per share reached $1.05. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;